Experience with ospemifene in patients with vulvar and vaginal atrophy and a history of breast cancer: case studies

Women with breast cancer are at a higher risk of developing vulvar and vaginal atrophy (VVA), a major component of the genitourinary syndrome of menopause, due to the combined estrogen-depleting effects of chemotherapy, adjuvant hormone therapy, and menopause. Ospemifene is approved to treat VVA in...

Descripción completa

Detalles Bibliográficos
Autores principales: Lilue, Mariella, Palacios, Santiago, del Carmen Pingarrón Santofimia, María
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioExcel Publishing Ltd 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337590/
https://www.ncbi.nlm.nih.gov/pubmed/32670380
http://dx.doi.org/10.7573/dic.2020-3-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337590/
https://www.ncbi.nlm.nih.gov/pubmed/32670380
http://dx.doi.org/10.7573/dic.2020-3-4

Ejemplares similares